Royalty Report: Alzheimer’s disease, Drugs, Diagnostic – Collection: 179565


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Alzheimer’s disease
  • Drugs
  • Diagnostic
  • Therapeutic
  • Medical
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 179565

License Grant
The Canadian University hereby grants to Licensee the exclusive royalty bearing right to use and practice, in the Field and in the Territory, the Licensed Patent(s) and the Licensed Intellectual Property with the exclusive right to make, have made, sell, lease or otherwise transfer the Licensed Product(s).
License Property
Licensed Patents(s) PCT/CA2014/050467 entitled Therapeutics for the Induction of Endogenous Steroidogenesis and Methods Associated with Their Identification filed on May 21, 2014, Published on December 18, 2014 (Publication No WO 2014/1979790.

Licensed Intellectual Property Product/Precursor Ions diagnostic of a DHEA Precursor Detected in Human Serum as Potential Biomarkers for the Determination of Alzheimer’s Disease. McGill ROI 15073.

Field of Use
This agreement pertains to the drug industry relating to Alzheimers Disease.

IPSCIO Record ID: 310824

License Grant
The Israel Licensee has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ®,

Pursuant to the agreement, the Licensor will receive royalty payments on the LymPro intellectual property in addition to being issued 49.9% of its ordinary shares in exchange for equity interest.

License Property
The LymPro intellectual property shall include the Lymphocyte Proliferation Test (LymPro Test®) which is a diagnostic blood test that determines the ability of peripheral blood lymphocytes to withstand an external mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons. LymPro is unique in the use of peripheral blood lymphocytes (PBLs) as a surrogate for neuronal cell function, suggesting a common immune-based relationship between PBLs and neurons in the brain.

Licensor is a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine to diagnose Alzheimer’s disease.

Field of Use
The field of use is to develop and commercialize the LymPro Test® for the detection of Alzheimer’s disease.

Licensee aims to develop and bring to market its revolutionary blood tests for disease detection that includes Alzheimers disease.

IPSCIO Record ID: 27552

License Grant
University has granted diagnostic rights to certain knowhow and patent rights relating to Alzheimer's Disease.

This Agreement initially contemplates a transfer of existing Alzheimer Therapeutic Know-how to Licensee. Pursuant to such initial transfer and continuing collaboration thereafter, it is contemplated that Licensee will determine the amino add sequence of proteins and base sequence of nucleic acids, generate monoclonal antibodies, done and express and assess biological and therapeutic activity of proteins, all related to the Field of this Agreement.

In addition, Licensee will engage in a collaborative research project directed to the Field and funded by Licensee, which collaboration is contemplated to include
a.  development by Licensee of therapeutics based on specific materials provided; and
b.  other related research and development related to the development by Licensee of therapeutics for Alzheimer's disease.

Field of Use
The field of use is therapeutics for Alzheimer's disease and precursor or related conditions, including any applications in other neurodegenerative diseases derived from the results of the research done under this Agreement.

IPSCIO Record ID: 125020

License Grant
University granted the Company a royalty bearing, exclusive worldwide license, limited to the field of Alzheimer’s Immunotherapy and Diagnostics.
License Property
United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use”, filed April 7, 2009 and granted May 29, 2012.
Field of Use
This agreement pertains to the drug industry relating to Alzheimer's Immunotherapy and Diagnostics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.